N/A N=30 Changes in Cerebral Oxygenation Based on Intraoperative Ventilation Strategy
Posterior Spinal Fusion
Primary: Change in Cerebral Oxygenation Values Throughout the Procedure — 83; 79; 81; 83 rSO2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,197 Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)
Prevention of Ebola Infection
Primary: Geometric Mean Titer of Anti-ZEBOV Glycoprotein Antibody — 1183.9; 1266.0; 1346.0; 1291.9 EU/mL — p=<0.001
N/A N=10 Clinical Study to Evaluate CryoBalloon™ Full and Swipe Ablation Systems for Ablation of Human Esophageal Epithelium
Esophageal Cancer
Primary: Safety of the CryoBalloon™ Full and Swipe Ablation System — 0; 0 Participants
Phase 1 N=40 Study of Food on Evacetrapib (LY2484595) in Healthy Participants
Healthy Volunteers
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Evacetrapib — 1140; 1720 nanograms/milliliter (ng/mL)
Phase 3 N=209 A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Change From Baseline in Disease Activity Score in 28 Joints Using 4 Variables (DAS28-4) (C-Reactive Protein [CRP]) at Week 12 — -2.43; -2.85 units on a scale
Phase 4 N=40 The PIO II Study: In-office Post-op Placement of a Steroid-eluting Sinus Implant
Chronic Sinusitis, Ethmoidal
Primary: Inflammation Score — 26.7; 26.8; 21.5; 17.6 units on a scale — p=0.4709
Phase 2 N=124 Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
Multiple Myeloma
Primary: Progression Free Survival (PFS) — 17; 25; 19 Participants
Phase 2 N=25 Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection
Hepatitis C, Chronic
Primary: Proportion of Subjects Achieving Sustained Viral Response at 12 Weeks After the End of Treatment. — 11; 10 Participants
Phase 4 N=57 Extended Release Niacin and Fenofibrate for the Treatment of Atherogenic Dyslipidemia in Obese Females
Atherogenic Dyslipidemia · Obesity Associated Disorder
Primary: Changes Serum Triglyceride Levels — 223.1; 241.2; 227.0; 267.2 mg/dl — p=0.0001
N/A N=10 A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer
Aerodigestive Tract Cancer · Lung Cancer · Esophageal Cancer
Primary: Changes in Tumor Markers on Tumors of the Lung, Esophagus, or Head and Neck, After 7 Days of Treatment With Vorinostat — 67; 40; 40 percentage of change
N/A N=162 Randomized Controlled Trial (RCT) of a Motivational Decision Support System
Schizophrenia
Primary: Number of Subjects That Initiated Cessation Treatment — 27; 36 participants
Phase 2 N=27 Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy
Prostate Cancer · Prostatic Neoplasms · Neoplasms, Prostate
Primary: Changes From Baseline to After Surgery of Cluster of Differentiation 4 (CD4) and Cluster of Differentiation 8 (CD8) Cell Infiltrates — 132.2; 153.7; 105.1; 140.5…
Phase 1 N=32 A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
Hepatic Insufficiency
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Time Tlast (AUC0-tlast) of Evacetrapib — 10700; 10500; 13200; 15800…
Phase 2 N=252 Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis
Endometriosis
Primary: Percent Change From Baseline in Bone Mineral Density of the Spine at Week 24 — -0.11; -1.29; -0.99 percent change
Phase 3 N=754 Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia
Hyperkalemia
Primary: Exponential Rate of Change in Serum Potassium (S-K) Levels During the Initial 48 Hours of Study Drug Treatment. — -0.00128; -0.00187; -0.00205; -0.00280 log(mmol/L)/hour